EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
139.39
+1.52 (+1.10%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close137.87
Open138.62
Bid0.00 x 3100
Ask0.00 x 800
Day's Range137.56 - 141.05
52 Week Range100.20 - 156.87
Volume1,392,541
Avg. Volume1,234,362
Market Cap29.186B
Beta0.72
PE Ratio (TTM)45.78
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
    PR Newswire15 days ago

    Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference

    IRVINE, Calif. , Aug. 2, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • ACCESSWIRE21 days ago

    Free Stock Performance Review on Boston Scientific and Three Additional Medical Equipment Stocks

    WallStEquities.com follows AxoGen Inc. (NASDAQ: AXGN), Boston Scientific Corp. (NYSE: BSX), Corindus Vascular Robotics Inc. (NYSE American: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances.

  • Edwards Lifesciences Reports Second Quarter Results
    PR Newswire21 days ago

    Edwards Lifesciences Reports Second Quarter Results

    IRVINE, Calif. , July 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Comments On CMS Advisory Panel
    PR Newswire22 days ago

    Edwards Comments On CMS Advisory Panel

    "Today's advisory panel meeting provided a review of current and possible future impacts of volume requirements on TAVR centers in the United States.  In the absence of definitive evidence linking high volumes of procedures to high quality outcomes for TAVR patients, we continue to believe the best course of action is to focus on defined quality measures for both new programs and also those continuing to offer this life-saving, less-invasive therapy.

  • Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018
    PR Newswirelast month

    Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018

    IRVINE, Calif. , July 12, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR
    PR Newswire2 months ago

    Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR

    CMS announced that it has opened the NCA to reconsider the National Coverage Determination (NCD) released in 2012 for TAVR. This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, June 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cabot ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Senseonics Holdings and Three More Medical Equipment Stocks

    Stock Research Monitor: EW, PBH, and VAR LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on SENS sign up now at www.wallstequities.com/registration . On Friday, June 22, 2018, ...

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Avinger and Three More Medical Equipment Stocks

    Under evaluation this morning are these four stocks: Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Redwood City, California headquartered Avinger Inc.'s stock finished last Friday's session 2.03% higher at $2.01.

  • Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
    PR Newswire3 months ago

    Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference

    IRVINE, Calif. , May 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
    PR Newswire3 months ago

    Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

    Study comparison shows results of almost 2,000 intermediate-risk patients at more than 450 U.S. centers PARIS , May 22, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader ...

  • Edwards Announces Key Events For EuroPCR 2018
    PR Newswire3 months ago

    Edwards Announces Key Events For EuroPCR 2018

    PARIS , May 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced ...

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire3 months ago

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 14, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • ACCESSWIRE3 months ago

    Free Post Earnings Research Report: Edwards Lifesciences’ Adjusted Sales Grew 9.3%; Adjusted EPS Surged 30%

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free earnings report on Edwards Lifesciences Corp. (NYSE: EW), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EW. Edwards Lifesciences reported its first quarter fiscal 2018 operating and financial results on April 24, 2018. Additionally, the Company provided guidance for the upcoming quarter and fiscal year.

  • Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement
    PR Newswire4 months ago

    Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

    Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.  Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

  • Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy
    PR Newswire4 months ago

    Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

    IRVINE, Calif., April 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction System for the treatment of tricuspid regurgitation. The Cardioband Tricuspid System is the first commercially available transcatheter therapy for the treatment of tricuspid heart valve disease. "Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation, despite evidence of increased mortality in these patients," said Prof. Georg Nickenig, chief, Department of Cardiology, University Hospital, Bonn, Germany.

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire4 months ago

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • ACCESSWIRE4 months ago

    Edwards Lifesciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Edwards Lifesciences Corporation (NYSE: EW ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern ...

  • Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018
    PR Newswire4 months ago

    Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018

    IRVINE, Calif. , April 10, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid
    PR Newswire5 months ago

    Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid

    WASHINGTON, March 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the United States Patent and Trademark Office (USPTO) decided in Edwards' favor in an Inter Partes Review (IPR) of Boston Scientific's U.S. transcatheter heart valve patent, number 8,992,608 (the '608 patent).  The USPTO determined that all claims of the '608 patent that have been asserted against Edwards are invalid.

  • Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe
    PR Newswire5 months ago

    Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

    IRVINE, Calif., March 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve. This randomized sub-study is examining leaflet mobility of both the SAPIEN 3 valve and surgical heart valves in low-risk patients undergoing valve replacement for the treatment of severe aortic stenosis. Enrollment in the PARTNER 3 main study of the SAPIEN 3 valve in low-risk patients was already complete.

  • Edwards' Acumen Hypotension Prediction Index Launches In The U.S.
    PR Newswire5 months ago

    Edwards' Acumen Hypotension Prediction Index Launches In The U.S.

    IRVINE, Calif., March 19, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the U.S. Food and Drug Administration granted the De Novo request for Edwards' Acumen Hypotension Prediction Index (HPI) software. The company will initiate a targeted launch of this first-of-its-kind technology that leverages predictive analytics to alert clinicians to address potential hypotension, or low blood pressure, before it occurs in their surgical patients. "Even brief periods of hypotension are associated with complications or, worse, death after surgery," said Maxime Cannesson, MD, PhD, Professor and Vice Chair, Department of Anesthesiology and Perioperative Medicine, at UCLA.

  • Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference
    PR Newswire5 months ago

    Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference

    IRVINE, Calif. , March 6, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...